Incannex Healthcare (ASX: IHL) has made several advances across its portfolio of cannabinoid and psychedelic medical therapies including generating positive preliminary safety and tolerability results of its anti-inflammatory drug IHL-675A during a phase 1 trial. IHL-675A is a fixed dose combination of cannabidiol (CBD) and hydroxychloroquine (HCQ) and has been designed to treat rheumatoid arthritis, […]
The post Incannex Healthcare advances cannabinoid and psychedelic medical therapies appeared first on Small Caps.
from Small Caps https://ift.tt/q2lkQz7
Post a Comment